Diabetic foot ulcers (DFUs) are a
common complication of diabetes, and with the increasing prevalence of diabetes
across all markets, the number of patients suffering from DFUs is also expected
to rise. Despite the availability of various treatment modalities, there are
currently few advanced wound care products available to treat hard-to-heal
chronic wounds. In addition, for the past 15 years, Regranex (becaplermin) has
been the only pharmacologic wound-healing agent available; however, it is
rarely used due a perceived lack of efficacy.
The DFU market is now set to enter
an exciting phase with the potential launch of three wound-healing agents in
the next five years; Olympus Biotechs trafermin (recombinant human basic
fibroblast growth factor), Macrocures CureXcell (activated leukocyte
suspension), and Derma Sciences DSC127 (NorLeu3-A[1-7]). The first two topical
antibacterials, Innocolls Cogenzia (gentamicin-collagen sponge) and Dipexium
Pharmaceuticals Locilex (pexiganan acetate cream 1%), are also expected to
launch in the US and the five major EU markets (5EU). Both pipeline agents
offer an alternative way to treat infection by localizing an antibiotic
directly at the wound site.
With the advent of these new product
launches, the size of the DFU market is expected to grow substantially during
the five-year forecast period.
Scope
* Overview of DFUs, including
epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines
* Annualized DFU therapeutics market
revenue, annual cost of therapy and treatment usage pattern data from 2012, and
forecast to 2017Key topics covered include strategic competitor assessment,
market characterization, unmet needs, clinical trial mapping and implications
* Pipeline analysis: comprehensive
data split across different phases, emerging novel trends under development,
and detailed analysis of late-stage pipeline drugs
* Analysis of the current and future
market competition in the global DFU therapeutics market. Insightful review of
the key industry drivers, restraints and challenges. Each trend is
independently researched to provide qualitative analysis of its implications.
Reasons to buy
* Develop and design your
in-licensing and out-licensing strategies through a review of pipeline products
and technologies, and by identifying the companies with the most robust
pipeline. Additionally a list of acquisition targets included in the pipeline
product company list.
* Develop business strategies by
understanding the trends shaping and driving the global DFU therapeutics
market.
* Drive revenues by understanding
the key trends, innovative products and technologies, market segments, and
companies likely to impact the global DFU therapeutics market in future.
* Formulate effective sales and
marketing strategies by understanding the competitive landscape and by
analysing the performance of various competitors.
* Identify emerging players with
potentially strong product portfolios and create effective counter-strategies
to gain a competitive advantage.
* Track drug sales in the global DFU
therapeutics market from 2012-2017.
* Organize your sales and marketing
efforts by identifying the market categories and segments that present maximum
opportunities for consolidations, investments and strategic partnerships.
To order this report:
Email: support@researchonglobalmarkets.com
US:
+1 866 325 7446
UK: +44 203 514 2363
India: +91 22 4098 7600
No comments:
Post a Comment